Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
A reminder that this weekend is Canadian Thanksgiving and the CCTG Central Offices will be closed on Monday, October 10th. All of the online applications will still be available and regular office hours resume on Tuesday October 11th at 8:30am. Happy Turkey Day!
Updated 5-year results of the Unicancer PRODIGE-24 | CCTG PA6 trial confirmed the significant improvement in all outcomes, including overall survival, with mFOLFIRINOX regimen compared to gemcitabine in adjuvant setting for for patients with pancreatic cancer has been published in JAMA Oncology.
CXC2 a Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer is now closed to accrual as the accrual target has been met.
Francais: Note de septembre 2022
September is Prostate Cancer Awareness Month and in 2020, 23,300 Canadian men were diagnosed with prostate cancer of which one third are estimated to have unfavourable risk, non-metastatic prostate cancer.
This story was published by Sunnybrooke Health Sciences Centre
From the Director’s Desk
September still feels like the beginning of a new year to me.
First results from the CCTG PR13 RADICALS: Radiotherapy and Androgen Deprivation In Combination After Local Surgery were presented at the European Society for Medical Oncology (ESMO) 2022 annual congress in Paris France on September 12.
CO28: NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial
Recently published in the Journal of Clinical Oncology
